ABT stock: buy or sell?
November 15th, 2019
Should I buy ABT stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Abbott Laboratories stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Abbott Laboratories stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 12 ratings published for ABT stock in the last month. The general sentiment of these ratings is bullish for ABT stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-14||BMO Capital Markets||n/a||n/a|
|2019-7-18||Jefferies Financial Group||n/a||Buy|
|2019-7-18||BMO Capital Markets||n/a||Outperform|
|2019-6-13||Wells Fargo & Co||n/a||Outperform|
|2019-6-13||Bank of America||n/a||Buy|
|2019-4-15||Royal Bank of Canada||n/a||Buy|
|2019-3-14||Wells Fargo & Co||n/a||Buy|
|2019-2-7||Bank of America||Buy||Buy|
ABT stock analysis
Shares of Abbott Laboratories rose a beatiful 1.89% and closed at $85.71.
Shares of Abbott Laboratories closed yesterday at $85.71 and rose a beatiful 1.89%. On Oct/9 ABT price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. From a daily perspective, ABT is in a short term uptrend after plotting its last bottom ($80.90, on November 5th) higher than the previous bottom, and its last top ($84.78, on Tuesday) also over the previous top. Now trading in between its last bottom and last top ABT might consolidate in a plain range, waiting to break out over $84.78 or down under $80.90. On July, ABT hit new all time highs, pushing higher previous ATH of $88.36 recorded on July. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Abbott Laboratories ended this week at $85.71 and escalated a good 2.35%. For 3 weeks in a row, price climbed and marked a profit of 4.90%.
ABT shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $78.20 early October. Previous top ($88.41) will play as a resistance in possible new gains. Far behind is the all-time high Abbott Laboratories hit late July but price is just -3.05% below that top. Since price and SMA20w lines crossed up this week, ABT climbed $1.97 (2.35%).
ABT stock price history
ABT stock went public on March 17th, 1980 with a price of $0.001. Since then, ABT stock surged a inf%, with a yearly average of inf%. If you had invested $1,000 in ABT stock in 1980, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
ABT stock historical price chart
ABT stock reached all-time highs on July with a price of $88.41.
ABT stock price target is $90.80How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ABT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 9 price targets for Abbott Laboratories stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-18||Raymond James||Raises Target||$87.00||$93.00||6.9%|
|2019-7-18||Jefferies Financial Group||Raises Target||$80.00||$98.00||22.5%|
|2019-7-18||BMO Capital Markets||Raises Target||n/a||$94.00||-|
|2019-7-16||Morgan Stanley||Raises Target||$85.00||$93.00||9.4%|
|2019-6-13||Wells Fargo & Co||Raises Target||$89.00||$91.00||2.2%|
|2019-6-13||Bank of America||Raises Target||$81.00||$90.00||11.1%|
|2019-4-15||Royal Bank of Canada||Raises Target||n/a||$82.00||-|
|2019-2-7||Bank of America||Reiterates||$73.00||$81.00||11%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Abbott Laboratories . As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a brilliant increase of 11.64% to $30,578.00 million USD. When comparing 2018 vs 2017, on the other hand, profit margin (that is, the net income divided by revenues) jumped a 6.00% to 7.74%. Abbott Laboratories presents anual results in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Abbott Laboratories TTM sales up to March 2019 were $30,723.00 and income $2,622.00 million USD. When comparing this TTM figures with the last reported annuality, we can esteem Abbott Laboratories business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, stayed steady a neutral 0.47%. Regarding profit margin, Abbott Laboratories remained steady 0.79% to 7.74%
|2013||$19,660 M||-||$1,970 M10.0%||-|
|2014||$20,247 M||2.99%||$2,284 M11.3%||15.94%|
|2015||$20,405 M||0.78%||$4,423 M21.7%||93.65%|
|2016||$20,853 M||2.20%||$1,400 M6.7%||-68.35%|
|2017||$27,390 M||31.35%||$477 M1.7%||-65.93%|
|2018||$30,578 M||11.64%||$2,368 M7.7%||396.44%|
|TTM||$30,723 M||0.47%||$2,622 M8.5%||10.73%|
Quarterly financial resultsAbbott Laboratories reported $7,535.00 M in revenues for 2019-Q1, a -2.96% decline compared to previous quarter. Reported quarter earnings marked $672.00 M with a profit margin of 8.92%. Profit margin stayed stable a 0.50% compared to previous quarter when profit margin was 8.42%. When comparing sales to same quarter last year, Abbott Laboratories sales marked a slightly fine growth and appreciated a 1.96%.
|2017-Q2||$6,640 M||-||$269 M4.1%||-|
|2017-Q3||$6,830 M||2.86%||$558 M8.2%||107.43%|
|2017-Q4||$7,589 M||11.11%||$-828 M-10.9%||-248.39%|
|2018-Q1||$7,390 M||-2.62%||$418 M5.7%||-150.48%|
|2018-Q2||$7,767 M||5.10%||$733 M9.4%||75.36%|
|2018-Q3||$7,656 M||-1.43%||$563 M7.4%||-23.19%|
|2018-Q4||$7,765 M||1.42%||$654 M8.4%||16.16%|
|2019-Q1||$7,535 M||-2.96%||$672 M8.9%||2.75%|
Abbott Laboratories ownershipWhen you are planning to invest in a stock, it's worth to review its ownership structure.
Abbott Laboratories shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.72% of all shares.
In case of Abbott Laboratories stock, 76.49% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ABT stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$151.7 B||$95.5 B||$58.8 B||$12.6 B||$354.9 B|
|Total shares||1,770.0 M||1,630.0 M||1,390.0 M||267.3 M||2,630.0 M|
|Float shares||1,760.0 M||1,630.0 M||1,390.0 M||267.9 M||2,630.0 M|
|- Institutional holdings (%)||76.5%||75.0%||93.4%||99.7%||69.2%|
|- Insider holdings (%)||0.7%||0.1%||0.2%||0.3%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$84.40 - $85.71|
|Average true range||$1.18|
|50d mov avg||$82.39|
|100d mov avg||$83.70|
|200d mov avg||$80.43|
Abbott Laboratories performanceTo better understand Abbott Laboratories performance you must compare its gains with other related stocks in same sector or industry. For Abbott Laboratories, the comparison is made against Bristol-Myers Squibb, Boston Scientific, Hologic, , Medtronic, Mylan, Pfizer and Thermo Fisher Scientific.
|TMOThermo Fisher Sci...||11.18%||17.38%||27.62%|
Abbott Laboratories competitorsWe chose a few stocks to conform a list of Abbott Laboratories competitors to watch if you are interested in investing in ABT:
- Bristol-Myers Squibb (BMY)
- Boston Scientific (BSX)
- Hologic (HOLX)
- Medtronic (MDT)
- Mylan (MYL)
- Pfizer (PFE)
- Thermo Fisher Scientific (TMO)
Latest ABT stock news
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Surges on Guidance, Q2 BeatJuly 17, 2019
- Seeking AlphaAbbott Laboratories: A Solid Business For An Attractive ValuationMay 8, 2019
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Down After Q1 BeatApril 17, 2019
- InvestorPlaceAll Signals Are Positive for Buying Abbott LaboratoriesJanuary 22, 2019
- InvestorPlace3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott LaboratoriesJanuary 4, 2019